Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2

Abstract

Background Activated factor V (FVa) is a potent procoagulant cofactor in the prothrombinase complex, whereas its precursor factor V (FV) stimulates the inhibition of factor Xa (FXa) by tissue factor pathway inhibitor-α (TFPIα), presumably by promoting TFPIα binding to phospholipids. Plasma FV comprises two glycosylation isoforms (FV1 and FV2) with low and high phospholipid-binding affinity, respectively. The FV1/FV2 ratio is increased in carriers of the FV R2 haplotype.

Objective This article demonstrates the TFPIα-cofactor function of FV in plasma and compares FV1 and FV2.

Materials and Methods Thrombin generation at low TF concentration was measured in FV-depleted plasma reconstituted with 0 to 100% FV, FV1 or FV2, and in 122 individuals genotyped for the R2 haplotype. The TFPIα-cofactor activities of FV1 and FV2 were also investigated in a model system of TFPIα-mediated FXa inhibition.

Results In the FV titration, thrombin generation first increased (up to 5% FV) and then progressively decreased at higher FV concentrations. This anticoagulant effect of FV, which was also observed with FV2 but not with FV1, was largely abolished by anti-TFPIα antibodies, suggesting that it reflects TFPIα-cofactor activity of FV. In the model system of TFPIα-mediated FXa inhibition, FV2 was a more potent TFPIα-cofactor than FV1, in line with their respective phospholipid affinities. Accordingly, FV R2 carriers had higher thrombin generation than non-carriers, even after correction for demographics and plasma levels of coagulation factors and inhibitors.

Conclusion FV (and particularly its FV2 isoform) contributes to the TFPIα-dependent down-regulation of thrombin generation in plasma triggered with low TF.

Keywords

factor V - tissue factor pathway inhibitor - R2 haplotype - thrombin generation - phospholipids

• References

• 1 Dahlbäck B. Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S. J Thromb Haemost 2017; 15 (07) 1241-1250
• 2 Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry 1990; 29 (05) 1118-1128
• 3 Camire RM, Bos MH. The molecular basis of factor V and VIII procofactor activation. J Thromb Haemost 2009; 7 (12) 1951-1961
• 4 Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255 (01) 274-283
• 5 Dahlbäck B, Villoutreix BO. The anticoagulant protein C pathway. FEBS Lett 2005; 579 (15) 3310-3316
• 6 Camire RM. Rethinking events in the haemostatic process: role of factor V and TFPI. Haemophilia 2016; 22 (Suppl. 05) 3-8
• 7 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269 (29) 18735-18738
• 8 Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage requirements for activation of factor V by factor Xa. Eur J Biochem 1997; 247 (01) 12-20
• 9 Vincent LM, Tran S, Livaja R, Bensend TA, Milewicz DM, Dahlbäck B. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα. J Clin Invest 2013; 123 (09) 3777-3787
• 10 Duckers C, Simioni P, Spiezia L. , et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 2008; 112 (09) 3615-3623
• 11 Mast AE, Broze Jr GJ. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood 1996; 87 (05) 1845-1850
• 12 Peraramelli S, Thomassen S, Heinzmann A. , et al. Role of exosite binding modulators in the inhibition of Fxa by TFPI. Thromb Haemost 2016; 115 (03) 580-590
• 13 Santamaria S, Reglińska-Matveyev N, Gierula M. , et al. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation. J Biol Chem 2017; 292 (22) 9335-9344
• 14 Ndonwi M, Girard TJ, Broze Jr GJ. The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va. J Thromb Haemost 2012; 10 (09) 1944-1946
• 15 Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A 2013; 110 (44) 17838-17843
• 16 Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol 2016; 36 (01) 9-14
• 17 Ndonwi M, Tuley EA, Broze Jr GJ. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood 2010; 116 (08) 1344-1351
• 18 Hackeng TM, Seré KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A 2006; 103 (09) 3106-3111
• 19 Ndonwi M, Broze Jr G. Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost 2008; 6 (06) 1044-1046
• 20 Ahnström J, Andersson HM, Hockey V. , et al. Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S. Blood 2012; 120 (25) 5059-5062
• 21 Maurissen LF, Castoldi E, Simioni P, Rosing J, Hackeng TM. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost 2010; 8 (04) 750-758
• 22 Rosing J, Bakker HM, Thomassen MC, Hemker HC, Tans G. Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem 1993; 268 (28) 21130-21136
• 23 Nicolaes GA, Villoutreix BO, Dahlbäck B. Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. Biochemistry 1999; 38 (41) 13584-13591
• 24 Hoekema L, Nicolaes GA, Hemker HC, Tans G, Rosing J. Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways. Biochemistry 1997; 36 (11) 3331-3335
• 25 Váradi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb Haemost 1996; 76 (02) 208-214
• 26 Lunghi B, Iacoviello L, Gemmati D. , et al. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996; 75 (01) 45-48
• 27 Bernardi F, Faioni EM, Castoldi E. , et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90 (04) 1552-1557
• 28 Castoldi E, Rosing J, Girelli D. , et al. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost 2000; 83 (03) 362-365
• 29 Hoekema L, Castoldi E, Tans G. , et al. Functional properties of factor V and factor Va encoded by the R2-gene. Thromb Haemost 2001; 85 (01) 75-81
• 30 Alhenc-Gelas M, Nicaud V, Gandrille S. , et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999; 81 (02) 193-197
• 31 de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000; 83 (04) 577-582
• 32 Nicolaes GAF, Tans G, Thomassen MCLGD. , et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270 (36) 21158-21166
• 33 Hemker HC, Giesen P, AlDieri R. , et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32 (5-6): 249-253
• 34 van Doorn P, Rosing J, Wielders SJ, Hackeng TM, Castoldi E. The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg¹⁵⁴⁵ cleavage site. J Thromb Haemost 2017; 15 (01) 140-149
• 35 Hackeng TM, Suijlen DPL, Hemker HC. , et al. Thermostable inhibitors of activation of the blood clotting system through contact with foreign surfaces. Google Patents; 2013
• 36 Segers O, Simioni P, Tormene D. , et al. Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. J Thromb Haemost 2012; 10 (01) 73-80
• 37 Segers O, Simioni P, Tormene D, Castoldi E. Influence of single nucleotide polymorphisms on thrombin generation in factor V Leiden heterozygotes. Thromb Haemost 2014; 111 (03) 438-446
• 38 Hackeng TM, Rosing J. Protein S as cofactor for TFPI. Arterioscler Thromb Vasc Biol 2009; 29 (12) 2015-2020
• 39 Dielis AW, Castoldi E, Spronk HM. , et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6 (01) 125-131
• 40 Castoldi E, Brugge JM, Nicolaes GA, Girelli D, Tans G, Rosing J. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004; 103 (11) 4173-4179
• 41 Al Dieri R, Bloemen S, Kelchtermans H, Wagenvoord R, Hemker HC. A new regulatory function of activated factor V: inhibition of the activation by tissue factor/factor VII(a) of factor X. J Thromb Haemost 2013; 11 (03) 503-511
• 42 Suehisa E, Kawasaki T, Toku M, Hidaka Y. Low level of factor V is associated with development of deep-vein thrombosis in Japanese patients. Thromb Res 2010; 125 (02) 128-133